A d-peptide-based oral nanotherapeutic modulates the PD-1/PD-L1 interaction for tumor immunotherapy

BACKGROUND: PD-1/PD-L1 immune checkpoint inhibitors are currently the most commonly utilized agents in clinical practice, which elicit an immunostimulatory response to combat malignancies. However, all these inhibitors are currently administered via injection using antibody-based therapies, while th...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Dan, Wang, Jingmei, You, Weiming, Ma, Fang, Sun, Qi, She, Junjun, He, Wangxiao, Yang, Guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388715/
https://www.ncbi.nlm.nih.gov/pubmed/37529049
http://dx.doi.org/10.3389/fimmu.2023.1228581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388715/
https://www.ncbi.nlm.nih.gov/pubmed/37529049
http://dx.doi.org/10.3389/fimmu.2023.1228581

Ejemplares similares